Welcome to Markets Desk, here's what's moving the tape this hour.
PTC Therapeutics is raising five hundred million dollars through convertible senior notes due twenty thirty one, pricing that deal at a conversion premium that puts the implied share price at roughly one hundred seven dollars and forty eight cents. Simultaneously, the biotech is retiring existing twenty twenty six notes, a classic liability management move designed to extend the runway while the convertible market remains receptive to growth-stage issuers.
That biotech financing comes against a broader backdrop of accelerating biopharma dealmaking. Top bankers at CNBC's conference flagged that major pharma companies are racing to replenish pipelines before a wave of patent expirations hits later this decade. The IPO window is cracking open, but large-cap acquisitions are still the dominant force pulling capital through the sector.
Shifting to commodities, coffee markets are surging on weather anxiety out of Brazil. July arabica futures are up more than two percent, hitting a two-week high, while robusta climbed to its strongest level in five weeks. Persistent rainfall in key Brazilian growing regions is raising concerns about crop quality and harvest logistics, and traders are pricing that uncertainty in aggressively.
That's the tape. Markets Desk, signing off the floor.
